Isu Abxis Obtains Chinese Patent for Anticancer Drug Candidate

[Asia Economy Reporter Seongpil Cho] ISU Abxis announced on the 25th that it has obtained a patent in China for its anticancer drug candidate 'ISU104' (generic name: varecetumab). This is the seventh patent acquired after registrations in six countries. The patent pertains to an antibody that specifically binds to ErbB3 for the treatment of cancers in which the ErbB3 protein is activated or overexpressed and that are resistant to anticancer drugs inhibiting ErbB1 or ErbB2.